Effect of short‐term intensive insulin therapy on quality of life in type 2 diabetes

Rationale, aims and objectives Short‐term intensive insulin therapy (IIT) early in the course of type 2 diabetes can improve pancreatic beta‐cell function and even induce normoglycemia that persists post‐therapy. In spite of this benefit, insulin is often delayed until late in the course of disease partly because of its perceived negative impact on quality of life (QOL). Therefore, we sought to examine the effect of early implementation of short‐term IIT on patient‐reported QOL and treatment satisfaction. Methods A total of 34 patients with type 2 diabetes (5.9 ± 6.6 years duration, on zero to two oral antihyperglycaemic agents) underwent 4–8 weeks of IIT consisting of basal detemir and pre‐meal insulin aspart. Patient‐reported QOL, treatment satisfaction and symptom distress were assessed at baseline and post‐IIT using the Medical Outcomes Study 36‐item Short‐Form Health Survey (SF‐36), Diabetes Quality of Life Measure (DQOL), and Diabetes Symptoms Checklist‐Revised (DSC‐R). Results There was a significant improvement in glycated haemoglobin post‐IIT (mean 6.5% vs. 7%; P < 0.001). All 34 patients tolerated IIT well with no severe hypoglycaemia. Following IIT, the SF‐36 showed a significant improvement compared to baseline in reported physical functioning (mean 88.2 vs. 83.3, P = 0.009), general health (69.4 vs. 65.6, P = 0.03), and general mental health (85.2 vs. 82.2, P = 0.04). The DQOL demonstrated a significant improvement in global health perception (P = 0.02), diabetes worry (P = 0.006) and treatment satisfaction (P = 0.007). The DSC‐R revealed a significant improvement in the diabetes‐related total symptom score (P = 0.01). Conclusions Contrary to popular perception, a short course of IIT resulted in significant improvements in QOL and treatment satisfaction, demonstrating the patient acceptability of early insulin therapy.